Immunotherapy for chronic myelocytic leukemia

Details Immunotherapy for chronic myelocytic leukemia Immunotherapy for chronic myelocytic leukemia

2004-05-26

2008-01-29

Yaen, Christopher (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Reexamination Certificate

active

07323168

ABSTRACT:
Immunotherapy utilizing naked anti-granulocyte antibodies provides an effective means for treating chronic myelocytic leukemia (CML). Such antibodies can be administered alone or in combination with other therapies, such as immunoconjugates or chemotherapeutics. In either format, an effective therapy for treating CML is provided, which avoids the toxic side-effects typically associated with cancer therapy. The disclosed immunotherapy also is effective for treating acute myelocytic leukemia (AML) when co-administered with inducing agents which induce expression of antigens minimally displayed on the surface of myeloblasts.

REFERENCES:
patent: 4904596 (1990-02-01), Hakomori
patent: 2279474 (2000-01-01), None
Jurcic et al (Clin. Cancer Res. Feb. 2000; 6:372-380).
Kossman et al (Clin. Cancer Res. Oct. 1999;5:2748-2755).
Jurcic et al (Leukemia Feb. 1995, 9(2);244-248).
Warrell RP et al (Leukemia Jun. 1994;8(6):929-933).
Shen et al (Blood May 1997; 89(9):3354-3360).
Chen et al (Blood May 1997; 89(9):3345-3353).
P. Caron et al., “Supersaturating Infusional Humanized Anti-CD33 Monoclonal Antibody HuM195 in Myelogenous Leukemia1,” Clinical Cancer Research, Jun. 1998, pp. 1421-1428, vol. 4.
H. Hansen et al., “Characterization of Second-Generation Monoclonal Antibodies Against Carcinoembryonic Antigen”, Cancer, Jun. 1993, pp. 3478-3485, vol. 71, No. 11.
J. Kotzerke et al., “Use of Re-188-Labeled Anti NCA-95 Antibodies in Treatment of Leukemia: First Results”, Journal of Nuclear Medicine, May 1999, vol. 40, No. 5, Abstract.
R. Di Noto et al., “In Vitro Treatment of APL Cells with Arsenic Trioxide (As2O3) Results in a Highly Specific Induction of Solitary CD66c Display”, Blood, Nov. 1997, vol. 90, No. 10, Abstract.
Seybold K. (Nuclear Medicine Communications, (1988) 9/10:745-752).

Affiliated with

Also associated with

Rating

Immunotherapy for chronic myelocytic leukemia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunotherapy for chronic myelocytic leukemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapy for chronic myelocytic leukemia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3962368